2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1557

Treatment Patterns in Psoriatic Arthritis: Experience from a Real-World Setting
Abstract Number: 1564

Treatment Patterns, Survival and Long-Term Effectiveness of Biological Agents in Psoriatic Arthritis Patients
Abstract Number: 937

Treatment Response in Polyarticular JIA Is Associated with Transcriptional Changes and Chromatin Reorganization in CD4+ T Cells
Abstract Number: 749

Treatment with Cyclophosphamide for Systemic Sclerosis-Interstitial Lung Disease Does Not Lead to a Sustained Improvement in Lung Function in Two Independent Cohorts
Abstract Number: 2067

Treatment with Pegloticase Significantly Decreases Mean Arterial Blood Pressure in Patients with Chronic Gout
Abstract Number: 2654

Treatment-Associated DNA Methylation Patterns in Systemic Lupus Erythematosus
Abstract Number: 1952

Trend of Arthrocentesis Utilization Among Inpatients over 10 Years – Data from National Inpatient Sample
Abstract Number: 856

Trends and Predictors of Chronic Opioid Use in Individuals with RA
Abstract Number: 2390

Trends and Predictors of Guideline Adherence for Glucocorticoid-Induced Osteoporosis Prevention in an Early Rheumatoid Arthritis Cohort
Abstract Number: 1032

Trends in Hospitalizations Following Heart Failure Diagnosis in Rheumatoid Arthritis
Abstract Number: 2505

Trends in Time to Diagnosis in Spondyloarthritis Patients. Association with 2009 ASAS Classification Criteria and Clinical Presentation at Disease Onset. Data from Comospa Study
Abstract Number: 2670

Trigeminal Neuralgia in Systemic Sclerosis
Abstract Number: 2689

Troponinemia Independently Associates with Mortality in Systemic Sclerosis
Abstract Number: 2787

Tuberculosis, Potential Opportunistic Infections, and Other Infections of Interest in Patients with Moderate to Severe Rheumatoid Arthritis in the Baricitinib Program
Abstract Number: 2127

Tumor Necrosis Factor Inhibitors for Sarcoidosis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].